[A17-32] Ceritinib (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 02.11.2017
Project no.:
A17-32
Commission:
Commission awarded on 20.07.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with advanced ALK-positive NSCLC
Added benefit not proven due to the lack of similarity of the indirectly compared studies
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-62 | Ceritinib (lung cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A15-24 | Ceritinib - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2019-02-01 A G-BA decision was published.